{
  "nct_id": "NCT55577639",
  "indication": "Parkinson's Disease",
  "phase": "Phase 1/2",
  "sample_size": 21,
  "duration_weeks": 5,
  "dropout_rate": 0.04,
  "blinding": "double-blind",
  "control_arm": "placebo",
  "primary_endpoints": [
    "UPDRS score improvement"
  ],
  "secondary_endpoints": [
    "OFF time reduction",
    "ON time without dyskinesia"
  ],
  "outcome_summary": "Met all pre-specified efficacy endpoints with favorable safety profile",
  "success": 1,
  "start_date": "2024-12-16",
  "completion_date": "2025-01-20"
}